|
gptkbp:instanceOf
|
gptkb:drug
cholesterol absorption inhibitor
|
|
gptkbp:approvalYear
|
2002
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:C10AX09
|
|
gptkbp:bioavailability
|
unknown
|
|
gptkbp:brand
|
gptkb:Ezetrol
gptkb:Zetia
|
|
gptkbp:CASNumber
|
gptkb:163222-33-1
|
|
gptkbp:chemicalClass
|
beta-lactam
|
|
gptkbp:combinationProduct
|
gptkb:Liptruzet
gptkb:Vytorin
|
|
gptkbp:combines
|
gptkb:atorvastatin
gptkb:simvastatin
|
|
gptkbp:contraindication
|
active liver disease
|
|
gptkbp:cost
|
generic available
|
|
gptkbp:developedBy
|
gptkb:Schering-Plough
|
|
gptkbp:discoveredBy
|
gptkb:Bruce_D._Roth
|
|
gptkbp:effect
|
lowers LDL cholesterol
reduces total cholesterol
|
|
gptkbp:eliminationHalfLife
|
22 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasMolecularFormula
|
C24H21F2NO3
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ezetimibe
|
|
gptkbp:KEGGID
|
D04022
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:liverMetabolism
|
glucuronidation
|
|
gptkbp:marketedAs
|
2002
|
|
gptkbp:mechanismOfAction
|
inhibits NPC1L1 protein
|
|
gptkbp:MedlinePlusID
|
a603015
|
|
gptkbp:MeSH_ID
|
D000068879
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:patent
|
1996
|
|
gptkbp:pregnancyCategory
|
C (US)
B3 (Australia)
not recommended in pregnancy
|
|
gptkbp:proteinBinding
|
99%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1201197
150311
DB00973
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
diarrhea
abdominal pain
fatigue
elevated liver enzymes
|
|
gptkbp:synonym
|
gptkb:Ezetimiba
gptkb:Ezetimibum
gptkb:SCH_58235
|
|
gptkbp:UNII
|
A256257SYN
|
|
gptkbp:usedFor
|
gptkb:familial_hypercholesterolemia
gptkb:sitosterolemia
|
|
gptkbp:bfsParent
|
gptkb:Vytorin
gptkb:Zetia
|
|
gptkbp:bfsLayer
|
5
|